Iranian Anti-Cancer Nanomedicine Finds Customers in Foreign States
“The albumin nanoparticles bound with paclitaxel (Paclinab) of our company designed and produced to treat cancer tissues have found success in the domestic markets and the market growth of this knowledge-based product has been so high that it was welcomed internationally and its exports started from the very first year,” said Navid Nateqian, the co-founder and a member of the board of directors of Nanodarou Pajouhan Pardis company.
He added that the anticancer nanomedicine has been produced for the treatment of breast, lung and pancreas cancers with the efforts of the researchers of the nanotechnology company.
“By penetrating into the cancerous tissue, the nanomedicine prevents the progress of tumor and destroys the cancerous tissue, and due to the nano dimensions of the drug, its effectiveness is higher and its side effects are less than similar medicine,” Nateqian said.
In a relevant development in September, researchers at an Iranian nanotechnology company had also succeeded in finding the formulation for production of nanoliposomal doxorubicin used for the treatment of cancer patients.
Ketabi, the marketing manager of Exir Nano Sina company, underlined the therapeutic effects of nanoliposomal doxorubicin in cancer treatment and the role of nanocurcumin in COVID-19 produced by the company.
He also referred to the production of first injectable anti-cancer nanomedicine product in the country with the scientific participation of Mashhad Faculty of Pharmacy, saying that these products are mainly made by lipid-based formulations in two forms of liposomal and nanomicelle.
Ketabi noted that using nanotechnology in these products increases their effectiveness and decreases their toxicity compared to other samples.
4155/v
